Option chain shows key data for Alumis's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Alumis.

Alumis (NASDAQ:ALMS) Stock, Option Chain

ALUMIS INC

Alumis

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.

Business,Man,Sign,A,Contract,Investment,Professional,Document,Agreement.,Meeting

News

Movers

ALMS

Alumis stock is trading higher on Tuesday after the company announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals.

What&#39;s Going On With Alumis Shares Tuesday?

Why It Matters

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

LQDA

OLLI

SRAD

TSLA

Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday

Palantir, Salesforce, Okta, Meta, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

ALVO

ATHM

BWMX

JBHT

JBLU

MDXG

TKNO

JB Hunt Transport Posts Weak Earnings, Joins JetBlue Airways And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Alumis Inc

Health Care

Press Releases

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

General

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Earnings

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

SLRN

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Biote

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Journey Medical Corporation - Common Stock

Journey Medical

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

MBX Biosciences

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Nektar Therapeutics

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

scPharmaceuticals

Septerna

SIGA Technologies

SNDL

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Third Harmonic Bio

Zhengye Biotechnology Holding Limited - Ordinary Shares

Comments

Alumis

Alumis (ALMS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga